JP2016512505A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512505A5
JP2016512505A5 JP2016500933A JP2016500933A JP2016512505A5 JP 2016512505 A5 JP2016512505 A5 JP 2016512505A5 JP 2016500933 A JP2016500933 A JP 2016500933A JP 2016500933 A JP2016500933 A JP 2016500933A JP 2016512505 A5 JP2016512505 A5 JP 2016512505A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
substituted
phenyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016500933A
Other languages
English (en)
Japanese (ja)
Other versions
JP6427551B2 (ja
JP2016512505A (ja
Filing date
Publication date
Priority claimed from US14/200,055 external-priority patent/US9050345B2/en
Application filed filed Critical
Publication of JP2016512505A publication Critical patent/JP2016512505A/ja
Publication of JP2016512505A5 publication Critical patent/JP2016512505A5/ja
Application granted granted Critical
Publication of JP6427551B2 publication Critical patent/JP6427551B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016500933A 2013-03-11 2014-03-10 カリウムイオンチャネル阻害剤としてのピロロトリアジン Expired - Fee Related JP6427551B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361775731P 2013-03-11 2013-03-11
US61/775,731 2013-03-11
US14/200,055 US9050345B2 (en) 2013-03-11 2014-03-07 Pyrrolotriazines as potassium ion channel inhibitors
US14/200,055 2014-03-07
PCT/US2014/022265 WO2014143610A1 (en) 2013-03-11 2014-03-10 Pyrrolotriazines as potassium ion channel inhibitors

Publications (3)

Publication Number Publication Date
JP2016512505A JP2016512505A (ja) 2016-04-28
JP2016512505A5 true JP2016512505A5 (enExample) 2017-04-13
JP6427551B2 JP6427551B2 (ja) 2018-11-21

Family

ID=51488539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500933A Expired - Fee Related JP6427551B2 (ja) 2013-03-11 2014-03-10 カリウムイオンチャネル阻害剤としてのピロロトリアジン

Country Status (8)

Country Link
US (1) US9050345B2 (enExample)
EP (1) EP2970296B1 (enExample)
JP (1) JP6427551B2 (enExample)
CN (1) CN105008367B (enExample)
AR (1) AR095208A1 (enExample)
TW (1) TW201444847A (enExample)
UY (1) UY35381A (enExample)
WO (1) WO2014143610A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2858987T (pt) * 2012-06-11 2018-07-04 Bristol Myers Squibb Co Profármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin -2-il]piridina-3-sulfonamida
US9403834B2 (en) * 2013-03-11 2016-08-02 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
JP2016516691A (ja) 2013-03-11 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カリウムイオンチャネル阻害剤としてのイソキノリン
CN105008366B (zh) 2013-03-11 2017-11-14 百时美施贵宝公司 作为钾离子通道抑制剂的吡咯并哒嗪类化合物
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US10292985B2 (en) 2015-08-31 2019-05-21 Bristol-Myers Squibb Company TGF beta receptor antagonists
CN105111154A (zh) * 2015-09-15 2015-12-02 上海瑞博化学有限公司 一种5-氨基吡嗪-2-甲酸合成新工艺
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
CN109415384B (zh) 2016-04-28 2022-01-11 武田药品工业株式会社 稠合杂环化合物
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
CA3198317A1 (en) * 2020-11-10 2022-05-19 Kevin J. Wilson Compounds and uses thereof
EP4504341A1 (en) 2022-04-08 2025-02-12 Shy Therapeutics LLC Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
AU2023270055A1 (en) 2022-05-11 2024-11-28 Foghorn Therapeutics Inc. Compounds and uses thereof
JP2026513122A (ja) * 2022-10-28 2026-04-23 上海深勢唯思科技有限責任公司 芳香族複素環式Kv1.3阻害剤、その製造方法及び用途
CN116063183B (zh) * 2023-01-28 2023-06-27 山东国邦药业有限公司 一种环丙胺的合成方法
WO2025077671A1 (zh) * 2023-10-09 2025-04-17 浙江海正药业股份有限公司 多取代芳基类衍生物及其制备方法和用途
WO2026019945A1 (en) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
TW202607004A (zh) * 2024-08-01 2026-02-16 大陸商浙江海正藥業股份有限公司 6,7-二氫-5H-吡咯並〔1,2a〕咪唑類衍生物及其製備方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
IL144977A0 (en) * 1999-05-21 2002-06-30 Bristol Myers Squibb Co Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
AU3276002A (en) * 2000-11-17 2002-05-27 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003265349A1 (en) 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
CN1771234A (zh) 2003-02-05 2006-05-10 布里斯托尔-迈尔斯斯奎布公司 吡咯并三嗪激酶抑制剂的制备方法
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
KR20070058602A (ko) 2004-09-30 2007-06-08 티보텍 파마슈티칼즈 리미티드 Hcv 저해 바이-사이클릭 피리미딘
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2007223342A1 (en) 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
WO2007107005A1 (en) 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
SI2041138T1 (sl) 2006-07-07 2014-08-29 Bristol-Myers Squibb Company Pirolotriazin kinazni inhibitorji
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2008131050A1 (en) 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2696631A1 (en) 2007-08-17 2009-02-26 Icagen, Inc. Heterocycles as potassium channel modulators
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
WO2009111531A1 (en) 2008-03-06 2009-09-11 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2010002472A1 (en) 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
US8445676B2 (en) * 2008-10-08 2013-05-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
EP2473487B1 (en) 2009-09-03 2016-10-26 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
PT2858987T (pt) * 2012-06-11 2018-07-04 Bristol Myers Squibb Co Profármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin -2-il]piridina-3-sulfonamida

Similar Documents

Publication Publication Date Title
JP2016514129A5 (enExample)
JP2016512504A5 (enExample)
JP2016516691A5 (enExample)
JP2014015465A5 (enExample)
JP2016006118A5 (enExample)
JP2015500843A5 (enExample)
JP2016534134A5 (enExample)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2013537203A5 (enExample)
JP2014530900A5 (enExample)
JP2016517417A5 (enExample)
JP2016531126A5 (enExample)
JP2016506960A5 (enExample)
JP2014506907A5 (enExample)
JP2017517538A5 (enExample)
JP2020527175A5 (enExample)
JP2016500661A5 (enExample)
JP2016528273A5 (enExample)
JP2017514855A5 (enExample)
JP2012532112A5 (enExample)
JP2016515560A5 (enExample)
RU2016115487A (ru) Тиазолопиримидиноны в качестве модуляторов активности рецепторов nmda
JP2017537937A5 (enExample)
JP2013527847A5 (enExample)
JP2015500223A5 (enExample)